{"url_path":"/sec/indp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","accession_number":"0001493152-26-023362","cik":"0001857044","ticker":"INDP","issuer_name":"Indaptus Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","primary_entity_key":"0001857044","primary_entity_name":"Indaptus Therapeutics, Inc."},"word_count":242,"has_tables":true,"body_markdown":"** **\n\n**Item\n6. Exhibits**\n\n** **\n\n**Exhibit\nNo.**\n \n**Exhibit\nDescription**\n\n31.1*\n \n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended](ex31-1.htm)\n\n31.2*\n \n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended](ex31-2.htm)\n\n32.1#\n \n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm)\n\n32.2#\n \n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm)\n\n101.INS*\n \nInline\nXBRL Instance Document\n\n101.SCH*\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n \nInline\nXBRL Taxonomy Extension Labels Linkbase Document\n\n101.PRE*\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)\n\n \n\nFiled herewith\n\nFurnished herewith\n\n \n\n6\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report\nto be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \nIndaptus\nTherapeutics, Inc.\n\n \n \n\nDate:\nMay 15, 2026\nBy:\n*/s/\nJunyi Dai*\n\n \n \nJunyi\nDai\n\n \n \n\nChief\nExecutive Officer\n\n(Principal\nExecutive Officer)\n\n \n \n \n\nDate:\nMay 15, 2026\nBy:\n*/s/\nYu Ding*\n\n \n \nYu\nDing\n\n \n \n\nChief\nFinancial Officer\n\n(Principal\nFinancial and Accounting Officer)\n\n \n\n7"}